2-氨基-7-氧代-4,5,6,7-四氢-1-苯并噻吩-3-羧酸乙酯 | 96334-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-氨基-7-氧代-4,5,6,7-四氢-1-苯并噻吩-3-羧酸乙酯
• 英文名称: ethyl 2-amino-7-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
• 英文别名: Ethyl 2-amino-7-oxo-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate；ethyl 2-amino-7-oxo-5,6-dihydro-4H-1-benzothiophene-3-carboxylate
• CAS: 96334-44-0
• 化学式: C₁₁H₁₃NO₃S
• mdl: MFCD00459036
• 分子量: 239.295
• InChiKey: KHNVFGZAADIYSH-UHFFFAOYSA-N

物化性质

• 熔点：
  208-209 °C
• 沸点：
  455.0±45.0 °C(Predicted)
• 密度：
  1.337±0.06 g/cm3(Predicted)
• 溶解度：
  34.7 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  97.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-氨基-7-氧代-4,5,6,7-四氢-1-苯并噻吩-3-羧酸乙酯 在 copper(I) oxide 、 甲醇 、 sodium hydroxide 、 水 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.25h， 生成 7-oxo-4,5,6,7-tetrahydrobenzothiophene-3-carboxylic acid
  参考文献：
  名称：

  Heterocyclic compound having oxime group

  摘要：

  本发明提供了一种对STAT6激活具有优异抑制活性且对过敏疾病有效的化合物及其药物组合物。根据本发明，公开了由通式（I）表示的化合物[其中R1和R2独立地表示可能具有氢原子或取代基等的C1-6烷基基团；R3表示可能具有取代基的C1-6烷基基团等；R4和R5独立地表示可能具有取代基的氢原子或C1-6烷基基团等；R6表示氢原子等；W表示—SO2—等；X表示硫原子等]或其盐或水合物。

  公开号：

  US20050227959A1
• 作为产物：
  描述：

  2-formylamino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester 在 potassium dichromate 、 氢氧化钾 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 1.0h， 生成 2-氨基-7-氧代-4,5,6,7-四氢-1-苯并噻吩-3-羧酸乙酯
  参考文献：
  名称：

  7-氧代-4,5,6,7-四氢苯并[b]噻吩和7-羟基苯并[b]噻吩的衍生物的合成和结构

  摘要：

  DOI：

  10.1007/bf00505954

文献信息

• [EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2019243550A1

  公开（公告）日：2019-12-26

  Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

  提供了公式（I）的噻吩衍生物及其药用可接受的盐。这些化合物对于治疗或预防由IgE引起的疾病具有用途，如过敏、1型超敏反应或家族性鼻窦炎。
• [EN] TOPICAL FORMULATIONS<br/>[FR] FORMULATIONS TOPIQUES
  申请人：NFLECTION THERAPEUTICS INC

  公开号：WO2020106304A1

  公开（公告）日：2020-05-28

  Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.

  本文提供了用于治疗皮肤疾病的凝胶局部制剂，包括：a) MEK抑制剂；b) 一种或多种有机溶剂，其重量约为70%至99%；和c) 凝胶剂；其中所述一种或多种有机溶剂选自以下组：C2-6醇，C2-6烷基二醇，二-(C2-6烷基)二醇，聚乙二醇，C1-3烷基-(OCH2CH2)1-5-OH，二甲基亚砜，乙酸乙酯，丙酮，N-甲基吡咯烷酮，苯甲醇，甘油和一种油；所述凝胶剂为分子量范围约为40,000 Da至2,500,000 Da的羟丙基纤维素；其中所述凝胶局部制剂的粘度为1至25,000 cps；当存在DMSO时，将DMSO与至少一种其他所述有机溶剂结合，使DMSO的重量不超过50%。
• Heterocyclic compound having oxime group
  申请人：Yoshida Ichiro

  公开号：US20050227959A1

  公开（公告）日：2005-10-13

  The present invention provides a compound that has an excellent inhibitory activity on STAT6 activation and is effective against allergic diseases, and a medicinal composition thereof. According to the present invention, disclosed is the compound represented by the General Formula (I) [where R 1 and R 2 independently represent a C 1-6 alkyl group and the like that may have a hydrogen atom or a substituent; R 3 represents a C 1-6 alkyl group and the like that may have a substituent; R 4 and R 5 independent represents a hydrogen atom or a C 1-6 alkyl group and the like that may have a substituent; R 6 represents a hydrogen atom and the like; W represents —SO 2 — and the like; and X represents a sulphur atom and the like.]or a salt thereof, or a hydrate thereof.

  本发明提供了一种对STAT6激活具有优异抑制活性且对过敏疾病有效的化合物及其药物组合物。根据本发明，公开了由通式（I）表示的化合物[其中R1和R2独立地表示可能具有氢原子或取代基等的C1-6烷基基团；R3表示可能具有取代基的C1-6烷基基团等；R4和R5独立地表示可能具有取代基的氢原子或C1-6烷基基团等；R6表示氢原子等；W表示—SO2—等；X表示硫原子等]或其盐或水合物。
• Discovery of new thiophene, pyrazole, isoxazole derivatives as antitumor, c-Met, tyrosine kinase and Pim-1 kinase inhibitors
  作者：R. M. Mohareb、K. M. H. Hilmy、Y. A. Elshehawy

  DOI：10.4314/bcse.v32i2.9

  日期：——

  The reaction of cyclohexan-1,3-dione (1) with ethyl orthoformate (2) in acetic acid gave the 2-(ethoxymethylene)cyclohexane-1,3-dione (3). The latter compound was used for further heterocyclization reactions to give thiophene, pyrazole and pyran derivatives. The cytotoxicity of the newly synthesized compound against the six cancer cell lines NUGC, DLDI, HA22T, HEPG2, HONE1 and MCF showed that compounds 5, 10c, 10d, 13b, 14a, 18b, 18d, 18e and 20b were the most potent compounds. On the other hand, the toxicity of these compounds against shrimp larvae indicated that compounds 7a, 10c, 13b, 14a, 18b and 18d were non toxic against the tested organisms. Inhibition of the most potent compounds towards the tyrosine kinases c-kit, FIT-3, Vascular Endothelial Growth Factor Receptor (VEGFR)-2, Estimated Glomerular Filtration Rate (EGFR) and Platelet-Derived Growth Factor Receptor (PDGFR) revealed that compounds 5, 10c, 10d, 13b, 18b, 18d, 18e and 20b were of the highest inhibitory effect. The Pim-1 kinase test revealed that compounds 10d, 18b and 20b were of the highest inhibitory effect. In addition, the c-Met enzymatic activities showed that compounds 10c, 10d, 18b, 18e, 19 and 20b showed higher potencies against c-Met kinase than the reference foretinib. On the other hand, compounds 7a, 7b, 10d, 13a, 13b, 14a, 14b, 16a, 16b, 17, 18a-f, 19 and 20 showed higher inhibition towards PC-3 cell line than the reference SGI-1776. Compounds 10c and 18b were of common potencies and their molecular docking was described.

  环己烷-1,3-二酮（1）与乙基邻福尔马酸酯（2）在醋酸中反应生成了2-(乙氧基亚甲基)环己烷-1,3-二酮（3）。后者化合物用于进一步的杂环化反应，生成噻吩、吡唑和吡喃衍生物。新合成化合物对六种癌细胞系NUGC、DLDI、HA22T、HEPG2、HONE1和MCF的细胞毒性显示化合物5、10c、10d、13b、14a、18b、18d、18e和20b是最有效的化合物。另一方面，这些化合物对虾幼虫的毒性测试表明，化合物7a、10c、13b、14a、18b和18d对所测试生物无毒。对酪氨酸激酶c-kit、FIT-3、血管内皮生长因子受体（VEGFR）-2、估计肾小球滤过率（EGFR）和血小板源性生长因子受体（PDGFR）的最有效化合物的抑制作用显示，化合物5、10c、10d、13b、18b、18d、18e和20b具有最高的抑制效果。Pim-1激酶测试表明化合物10d、18b和20b具有最高的抑制效果。此外，c-Met酶活性显示，化合物10c、10d、18b、18e、19和20b对c-Met激酶的活性高于参考化合物foretinib。另一方面，化合物7a、7b、10d、13a、13b、14a、14b、16a、16b、17、18a-f、19和20对PC-3细胞系的抑制作用高于参考化合物SGI-1776。化合物10c和18b具有相似的效力，其分子对接已被描述。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2009011A1

  公开（公告）日：2008-12-31

  The object of the present invention is to provide a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties such as efficacy, duration of activity, specificity, low toxicity and the like. The present invention provides a compound represented by the following formula wherein ring M is a 5- or 6-membered aromatic ring; W is C or N; K is an optionally substituted methylene group or an optionally substituted imino group; R is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted heterocyclic group; T and U are independently a hydrogen atom or a substituent or, T and U form, together with ring M, an optionally substituted bicyclic ring; D and G are independently a carbonyl group or a sulfonyl group; ring P is an optionally substituted piperidine or an optionally substituted piperazine; B is CH or N; ring Q is an optionally substituted monocyclic ring; A is C, CH or N; and J is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted amino group, provided that when the W moiety of ring M is =N- or -N=, then U should be absent, or a salt thereof.

  本发明的目的是提供一种具有ACC抑制作用的化合物，用于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等疾病，并具有诸如疗效、活性持续时间、特异性、低毒性等优越特性。本发明提供了以下式所表示的一种化合物，其中环M为5-或6-成员芳香环；W为C或N；K为可选择地取代的亚甲基基团或可选择地取代的亚胺基团；R为氢原子、可选择地取代的碳氢基团、可选择地取代的羟基或可选择地取代的杂环基团；T和U独立地为氢原子或取代基，或T和U与环M一起形成可选择地取代的双环环；D和G独立地为羰基或磺酰基；环P为可选择地取代的哌啶或可选择地取代的哌嗪；B为CH或N；环Q为可选择地取代的单环环；A为C、CH或N；J为可选择地取代的碳氢基团、可选择地取代的杂环基团或可选择地取代的氨基团，前提是当环M的W基团为=N-或-N=时，U应当不存在，或其盐。